Lipocalyx
Key Facts
| Invested since | 2011 |
| Based in | Saxony-Anhalt |
About the company
Lipocalyx provides leapfrog innovation for genetic research. Our Viromers® deliver the bits and pieces of DNA or RNA necessary to interfere with the genetic content of a cell. Viromers® take advantage of a viral fusion mechanism and, for the first time, translate this into polymer chemistry. As a result, we can reach into hard-to-transfect cells and enable siRNA or plasmid work there.
Lipocalyx started its marketing in Jan 2013 and announced a global network of distributors in Sep 2014.
Challenge: Transfection of resistant cells
Solution: Viromers, polymers using an Active Escape Technology
Business: Reagent provider & know-how provider around transfection, direct and distributor sales, co-developments
Technology: Active Endosome Escape for superior tranfection,
IP: Umbrella patent for Viromers, specific IP for products, trademarks
Market: Transfection market $283M, market potential for Viromers $80M
Customers: R&D in academia and industry, in particular those working with resistant or sensitive cells like primary cells or stem cells
Geography: Global Distribution
Competition: Life Technologies, offereing a one-stop solution for both siRNA and transfection is the most dominant player; strong brands, e.g.Fugene by Promega; electroporation (Lonza, BioRad) is currently used for resistant cells. Works well for plasmids, but not for siRNA.
Cell penetrating peptides may come up as competition ; in the future „downgrading“ of in vivo reagents may become a competition
Do you want to
know more about this company?
Lipocalyx in the news
More startups from Life Sciences
650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers …
lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family …
Reactive Robotics is a leading healthcare startup dedicated to developing innovative technologies and solutions for the healthcare industry. The company is on a mission to revolutionize healthcare by integrating technology …
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …
Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and …
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
GILUPI developed a nanostructured detector, which is temporarily inserted into the bloodstream. The aim is to spot specific blood cells in vivo and thus to detect diseases in a very …
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
